Unimed Pharmaceuticals, LLC, decides not to file a patent infringement suit at this time against Perrigo Israel Pharmaceuticals, LTD. following the receipt of a paragraph IV certification for a generic formulation of Androgel® 1%

The low volume formulation of AndroGel, for which an NDA was submitted to FDA in the first quarter of 2009, is not within the scope of Perrigo’s ANDA.

Contacts

Media Relations
Erik De Leye
+32 2 264 1530
Investor Relations
Patrick Verelst
+32 2 264 1540